Biotech

Helping biotech meet critical milestones.

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from genomic medicines to first-in-class immunotherapies. Typically focused on a small portfolio of compounds, or just a single compound, in a particular therapeutic indication, many biotechs lack the full spectrum of resources or infrastructure required to bring these novel therapies to market.

1
ICON has the world's largest dedicated biotech division
8,000
Staff dedicated to biotech customers
500+
ICON supports over 500 biotech sponsors annually

Our empowered structure enables flexibility and quick decision-making within the global reach one of the world’s biggest and most innovative CROs. Our biotech division of 8,000 people operates with a mindset aligned to small and mid-sized biopharma. Our tailored teams and management understand the different pressures that are faced by biotechs and will engage, collaborate and share ownership in the delivery of your clinical trials.

How ICON can help your company to reach key milestones at every stage of development:

Case studies

ICON helps biotechs to meet their critical milestones and deliver data and evidence-based results to investors, large pharma partners, regulatory authorities, and other stakeholders with responsiveness, accessibility, and true collaboration.

Learn more

Behind Biotech

Stories of science and resilience

Learn more

Early, precise and efficient

The methods and technologies advancing Alzheimer’s and Parkinson’s R&D.

Explore

ICON survey report

Exploring the application of methods and technologies advancing CNS therapeutic development.

Explore

Early phase challenges for biotechs

This whitepaper explores the growing challenges facing biotech during early phase drug development.

Explore

De-risking clinical development of precision medicines in oncology

This whitepaper reviews the most pressing challenges and opportunities facing the oncology therapeutic landscape.

Explore

Optimising biotech funding whitepaper series

In this two-part whitepaper series on biotech funding, we firstly share insights on how biotechs can secure funding in a highly competitive market.

Explore

2023 biotech sector survey

Navigating biotech's challenges and embracing a promising tomorrow.

Explore

Early engagement and regulatory considerations for biotech

Gain insight into the common questions small and emerging biotech companies face.

Explore

Procedural and regulatory know-how for China biotechs in the EU

Learn how to navigate the European Medicines Agency registration and regulation procedures.

Explore

Exploring partnership culture and its impact on outsourcing and operational strategy

Supporting, informing, and maintaining strategies and operational decision-making.

Explore

Biotech insights and media contributions

Media article: Insights and projections shaping the biotech industry

This article summarises the main findings from the biotech sector survey and outlines the key implications for biotech including strategic collaboration, innovation and cost optimisation.

Media article: Shaping the future of novel therapy development

In this article from Citeline, we discuss how drug innovation has the potential to benefit everyone, but it cannot exist in a vacuum. Today’s novel therapies are conceived and developed in a payer-patient- and value-oriented environment, one in which the gap between ambition and uptake is wider than ever.

Blog: Crafting a competitive biotech funding pitch

Biotechs can hone their pitch with the guidelines provided in this blog and through early engagement opportunities with strategic partners.

Blog: Optimising biotech trial designs to stretch your cash runway

Read this blog to learn a few key considerations to help optimise and de-risk your trial design.

Blog: The importance of developing rTPP to build biotech asset value

Discover how Biotechs can build value into their asset by developing a reimbursable Target Product Profile (rTPP).

Blog: Uncertainty to opportunity - Recent trends in the biotech funding environment

In this blog, discover more about how the biotech sector is transforming uncertainty into opportunity.

Blog: Exploring the benefits of biotech partnerships

The biotechnology sector is leading the way in developing innovative therapies that will address the unmet needs of many challenging diseases.

Media article: Moving Beyond a Buzzword

How small- to mid-sized biotechs can adopt patient centricity in their oncology trias.

Media article: Due diligence and beyond

Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment, to now being an integrated part of the holistic development continuum of an asset.

Media article: Europe’s emerging biotechs

John Macdonald, Vice President, Venture & Financial Alliances, examines the European biotech sector – its expertise and opportunities, and potential for growth.

Media article: Biotech funding

ICON plc has partnered with ALSA Ventures I SCSp, a Europe focused therapeutic venture capital fund, to accelerate early clinical development within the UK and the EU.